Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas (GlobeNewswire) - Oct 29, 2024 - "Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development: Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM; Company to host an educational symposium featuring clinical experts discussing LM and Plus' recent announcements for its LM therapeutic and diagnostic programs."
P1 data • CNS Tumor
|